Inhibrx Biosciences, Inc. (INBX) Form 8-K — Jul 16, 2026
Inhibrx Biosciences entered into a Second Amendment with Oxford Finance, expanding its total credit facility to $500.0 million. The agreement adds a $325.0 million tranche, with $100.0 million funded immediately as a Term C Loan and up to $225.0 million available for future draws at the company's request. To secure the new funding, Inhibrx issued warrants to purchase 21,457 shares at $93.21 per share, representing 2% of the Term C Loan value. The warrants are immediately exercisable and expire in ten years, while the company also pledged equity in subsidiary Poplar Therapeutics as collateral.
Key figures
- Debt Amount
- $500,000,000
- Offering Price
- $93.21
- Shares Offered
- 21457
- Prior draws
- $175,000,000
- Term c loan funded
- $100,000,000
- Warrant expiration
- 10 years
- Term d loan available
- $225,000,000
- Warrant coverage percent
- 2%
Price after filing
Close on the filing date to close N calendar days later (from $89.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.